Jonathan Gutman, MD
Professor, Medicine-Hematology

Research Interests

Publications

• Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2023 Dec 14. [Epub ahead of print] PubMed PMID: 38105738
• Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimarães-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, Aisner DL, Gutman JA. A Case of Fetal-Induced Graft-versus-Host Disease. N Engl J Med. 2023 Aug 17;389(7):668-670. PubMed PMID: 37585636
• Abidi MZ, Molina KC, Garth K, Gutman JA, Weinberg A. Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis. Transpl Infect Dis. 2023 Oct;25(5):e14104. PubMed PMID: 37436771
• Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 Aug;58(8):849-854. PubMed PMID: 37185614
• Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 Oct 1;108(10):2616-2625. PubMed PMID: 37051756
• Gutman JA. How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML. Best Pract Res Clin Haematol. 2022 Dec;35(4):101411. PubMed PMID: 36517129
• Zhang A, Johnson T, Abbott D, Phupitakphol T, Gutman JA, Pollyea DA, Koullias Y. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine. Open Forum Infect Dis. 2022 Oct;9(10):ofac486. PubMed PMID: 36225746
• Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 Sep;6:e2200030. PubMed PMID: 36194842
• Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax   Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022 Oct;28(10):694.e1-694.e9. PubMed PMID: 35902048
• Brewer B, Sharma P, Gakhar N, Sannes TS, Joshi TK, Hunter R, Abbott D, Gutman JA. Quality of life following cord blood versus matched sibling donor transplantation: pre-transplantation psychiatric and socioeconomic factors significantly impact outcomes. Bone Marrow Transplant. 2022 Aug;57(8):1344-1346. PubMed PMID: 35618765
• Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022 Feb;57(2):160-166. PubMed PMID: 34645926
• Blood type change identifies late dominance reversal of chimerism after double umbilical cord blood transplantation with review of the literature. Ho AP, Ho BE, Berg MP, Gutman JA, Draper NL.Transfusion. 2021 Feb 26.
• Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Bone Marrow Transplant. 2021 Oct 13.
• Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 Dec 28;5(24):5565-5573.
• Marc S. Schwartz, Enkhtsetseg Purev, Clayton Smith, Christine M. McMahon, Daniel A. Pollyea, Jonathan A. Gutman. Dasatinib Prednisone Is an Effective Induction Strategy Prior to Transplant for Philadelphia Chromosome Positive ALL. ASTCT 2021.
• Brett M. Stevens, Amanda C. Winters, Mohammad Minhajuddin, Maria L. Amaya, Christine M. McMahon, Jonathan A. Gutman, Clayton Smith, Deng Wang, Connor Adkins, Olivia Ondracek, Craig T. Jordan and Daniel A. Pollyea. Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies. ASH 2021.
• Michael T. Byrne, Tony J Kurian, Dilan A Patel, Roni Tamari, Sanghee Hong, Haitham Abdelhakim, Victoria Klein, Patricio Rojas, Raksha Madhavan, Andrew Kent, Aaron C. Logan, Catherine J. Lee, Muhammad Husnain, Benjamin M Manning, Nicholas P. Tschernia, Ajoy L. Dias, Daniel Margalski, Benjamin Goldenson, Nathalie Byrne, Heidi Chen, Kseniya Petrova-Drus, Salyka M. Sengsayadeth, Aaron M Goodman, Dianna S. Howard, William A. Wood, Saar Gill, Antonio M. Jimenez, Jonathan A. Gutman, Lohith Gowda, Leland Metheny III, Bhavana Bhatnagar, Betty K. Hamilton, Asmita Mishra, and Michael R. Savona. Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study. ASH 2021.
• Amanda C. Winters, Grace Bosma, Diana Abbott, Mohd Minhajuddin, Craig T Jordan, Daniel A. Pollyea and Jonathan A. Gutman. Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. ASH 2021.
• 51. Prashant Sharma, Neel Gakhar, Jennifer MacDonald, Maheen Abidi, Esther Benamu, Valida Bajrovic, Enkhtsetseg Purev, Bradley M. Haverkos, Jennifer Tobin, Jeff Kaiser, Stephanie Chase, Matthew Miller, Adriana Weinberg, and Jonathan A Gutman. Letermovir prophylaxis through day 100 post-transplant is safe and effective compared to alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020 Apr;55(4):780-786.
• 52. Gutman JA, Pollyea DA. Hypomethylating agents with venetoclax: have we discovered the holy grail? Curr Opin Hematol. 2020 Mar;27(2):76-80.
• 53. Shanshan Pei, Daniel A. Pollyea, Annika Gustafson, Brett M. Stevens, Mohammad Minhajuddin, Rui Fu, Kent A. Riemondy, Austin E. Gillen, Ryan M. Sheridan, Jihye Kim, James Costello, Maria L. Amaya, Anagha Inguva, Amanda Winters, Haobin Ye, Anna Krug, Courtney L. Jones, Biniam Adane, Nabilah Khan, Jessica Ponder, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes , Jason R. Myers, John M. Ashton, Travis Nemkov, Angelo D'Alessandro, Jonathan A. Gutman, Stephen W. Fesik, Haley E. Ramsey, Michael R. Savona , Clayton A. Smith, Craig T Jordan. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Cancer Discovery. 2020 Apr;10(4):536-551.
• 54. Prashant Sharma, Enkhtsetseg Purev, Bradley Haverkos, Daniel A. Pollyea, Evan Cherry, Manali Kamdar, Tomer Mark, Peter Forsberg, Daniel Sherbenou, Andrew Hammes, Rachel Rabinovitch, Clayton A. Smith, Jonathan A. Gutman. Adult cord blood transplant results in comparable overall survival and improved GRFS versus matched related transplant. Blood Advances. 2020 May 26;4(10):2227-2235.
• 55. Jason P. Cooper, Barry E. Storer, Noa Granot, Boglarka Gyurkocza, Mohamed L. Sorror, Thomas R. Chauncey, Judith Shizuru, Georg-Nikolaus Franke, Michael B. Maris, Michael Boyer, Benedetto Bruno, Firoozeh Sahebi, Amelia A. Langston, Parameswaran Hari, Edward D. Agura, Søren Lykke Petersen, Richard T. Maziarz, Wolfgang Bethge, Julie Asch, Jonathan A. Gutman, Gitte Olesen, Andrew M. Yeager, Kai Hübel, William J. Hogan, David G. Maloney, Marco Mielcarek, Paul J. Martin, Mary E. D. Flowers, George E. Georges, Ann E. Woolfrey, H. Joachim Deeg, Bart L. Scott, George B. McDonald, Rainer Storb, and Brenda M. Sandmaier. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haemalogica. 2020 Jun 4:haematol.2020.248187. Online ahead of print.
• 56. Andrew Kent, Sumithira Vasu, Derek Schatz, Natalie Monson, Steven Devine, Clayton Smith, Jonathan A. Gutman*, Daniel A. Pollyea* (shared senior authorship). Glasdegib as Maintenance Therapy for AML and MDS Patients at High Risk for Post-Allogeneic Stem Cell Transplant Relapse. Blood Advances. 2020 Jul 14;4(13):3102-3108.
• 57. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 May 1;18(5):599-634.
• 57. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 May 1;18(5):599-634.
• 58. Filippo Milano, Jonathan A Gutman, H. Joachim Deeg, Eneida R Nemecek, Joachim Baumgart, Laurel Thur, Ann Dahlberg, Rachel B Salit, Corinne Summers, Frederick R Appelbaum, Colleen Delaney. Treosulfan-based Conditioning is Feasibel and Effective for Cord Blood Recipients: A Phase II Multi-center Study. Blood Advances. 2020 Jul 28;4(14):3302-3310.
• 59. Matthew A Miller, PharmD, Kyle C Molina, PharmD, Jonathan A Gutman, MD, Sias Scherger, MD, Jessica M Lum, MD, Sherif B Mossad, MD, Mary Burgess, MD, Matthew P Cheng, MD, Sally T Chuang, MD, Samantha E Jacobs, MD, Dante P Melendez, MD, Dimpy P Shah, MD, Andrea Zimmer, MD, M Rizwan Sohail, MD, Sadia Syed, MD, Randall C Walker, MD, Eric M Poeschla, MD, Maheen Z Abidi, MD. Mucormycosis in Hematopoietic cell Transplant Recipients and in patients with Hematological Malignancies in the Era of New Antifungal Agents. Open Forum Infectious Diseases. 2020 12/30.
• 60. Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax?+?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2020 Dec 30:1-9. doi: 10.1080/10428194.2020.1864358. Online ahead of print.
• 57. Mangala Iyengar, Enkhtsetseg Purev, Brad Haverkos, Clayton Smith, Daniel Pollyea, Jonathan A Gutman. Incidence of Pulmonary GVHD is Increased and Incidence of Late Infection and Pulmonary Embolism is Comparable Comparing Adult MRD Versus Cord Transplant Patients. ASBMT 2020. Poster.
• 58. Matthew A Miller, Kyle C Molina, Sias Scherger, Jessica Lum, Sherif B Mossad, Mary Burgess, Matthew P Chang, Sally Chuang, Samantha Jacobs, Dante Melendez, Dimpy P Shah, M Rizwan Sohail, Sadia Syed, Randall C Walker, Andrea Zimmer, Jonathan A Gutman, Maheen Z Abidi. Survival Among Patients with Hematologic Malignancies and Recipients of Hematopoietic Cell Transplant with Invasive Mucormycosis. ASBMT 2020. Poster.
• 59. Hannah Choe, Nirav N. Shah, Patrice Chevallier, Marie Thérèse Rubio, Mark A. Schroeder, Nancy M. Hardy, Patrick J. Stiff, Carlos Solano, Ibrahim Yakoub-Agha, Jonathan A. Gutman, Scott D. Rowley, Maria Caterina Mico, Elisabetta Terruzzi, Rafael F. Duarte, Rodica Morariu-Zamfir, Michael Arbushites, Kai Ding, and Miguel-Angel Perales. A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)–Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119). ASH 2020. Oral.
• 60. Jonathan A. Gutman, Amanda Winters, Maria L Amaya, Christine M. McMahon, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes, Shanshan Pei, Brett M. Stevens, Craig T. Jordan, Clayton Smith and Daniel A. Pollyea. Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features. ASH 2020. Poster.
• 61. Daniel A. Pollyea, Amanda Winters, Craig T. Jordan, Clayton Smith, and Jonathan A. Gutman. Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy ASH 2020. Oral.
• 62. Andrew Kent, Daniel A. Pollyea, Amanda Winters, Craig T. Jordan, Clayton Smith, and Jonathan A. Gutman. Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse. ASH 2020. Poster.
• Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells. J Biol Chem. 2016 Nov 25;291(48):25280. PubMed PMID: 27888238
• Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14;291(42):21984-22000. PubMed PMID: 27573247
• Gavin KM, Gutman JA, Kohrt WM, Wei Q, Shea KL, Miller HL, Sullivan TM, Erickson PF, Helm KM, Acosta AS, Childs CR, Musselwhite E, Varella-Garcia M, Kelly K, Majka SM, Klemm DJ. De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue. FASEB J. 2016 Mar;30(3):1096-108. PubMed PMID: 26581599
• Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leuk Lymphoma. 2016;57(4):927-34. PubMed PMID: 26389776
• Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ. Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2014 Jan 16. [Epub ahead of print] PubMed PMID: 24440648
• Bird GA, Polsky A, Estes P, Hanlon T, Hamilton H, Morton JJ, Gutman J, Jimeno A, Turner BC, Refaeli Y. Expansion of human and murine hematopoietic stem and progenitor cells ex vivo without genetic modification using MYC and Bcl-2 fusion proteins. PLoS One. 2014;9(8):e105525. PubMed PMID: 25170611
• Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug;99(8):1277-84. PubMed PMID: 25082785
• Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. PubMed PMID: 24440648
• Babilonia KM, Golightly LK, Gutman JA, Hassell KL, Kaiser JN, Kiser TH, Klem PM, Trujillo TC. Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization. Clin Appl Thromb Hemost. 2014 Nov;20(8):799-806. PubMed PMID: 25022565
• Narayanan V, Gutman JA, Pollyea DA, Jimeno A. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. Drugs Today (Barc). 2013 Jul;49(7):447-56. PubMed PMID: 23914353
• Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc). 2013 Apr;49(4):261-9. PubMed PMID: 23616953
• Coffey DG, Pollyea DA, Myint H, Smith C, Gutman JA. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplant. 2013 Sep;48(9):1253-6. PubMed PMID: 23503530
• Ostronoff F, Milano F, Gooley T, Gutman JA, McSweeney P, Petersen FB, Sandmaier BM, Storb R, Delaney C. Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin. Bone Marrow Transplant. 2013 Jun;48(6):782-6. PubMed PMID: 23241738
• Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant. 2013 Mar;19(3):393-7. PubMed PMID: 23089564